ARCT logo

Arcturus Therapeutics Holdings Inc. (ARCT)

$7.97

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ARCT

Market cap

$249372605

EPS

-3.1

P/E ratio

--

Price to sales

18.77

Dividend yield

--

Beta

2.617658

Price on ARCT

Previous close

$8.31

Today's open

$8.32

Day's range

$7.69 - $8.53

52 week range

$5.50 - $17.96

Profile about ARCT

CEO

Joseph Payne

Employees

111

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

31288909

Issue type

Common Stock

ARCT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ARCT

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. (“Meiji”), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding (“MOU”) related to pandemic preparedness and response in Japan and an exclusive.

news source

Business Wire • Nov 16, 2026

news preview

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call

Arcturus Therapeutics NASDAQ: ARCT expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the first quarter of 2027, executives said on the company's third-quarter earnings call.

news source

MarketBeat • Nov 6, 2026

news preview

Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced its financial results for the quarter ended September 30, 2026, and provided corporate updates. “The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-genera.

news source

Business Wire • Nov 5, 2026

news preview

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.49 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter ended September 30, 2026, after the market close on Thursday, November 5th and will also host a conference call and webcast at 4:30 pm Eastern Time on November 5, 2026. Arcturus Therapeutics Third Quarter 2026 Earning.

news source

Business Wire • Oct 26, 2026

news preview

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

news source

Zacks Investment Research • Sep 28, 2026

news preview

Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.

news source

MarketBeat • Sep 25, 2026

news preview

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

news source

Seeking Alpha • Sep 24, 2026

news preview

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.

news source

Business Wire • Sep 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Arcturus Therapeutics Holdings Inc.

Open an M1 investment account to buy and sell Arcturus Therapeutics Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ARCT on M1